Page last updated: 2024-09-04

tipifarnib and Lymphoma

tipifarnib has been researched along with Lymphoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allmer, C; Ansell, SM; Colgan, JP; Ding, H; Gupta, M; Habermann, TM; Hohl, R; Inwards, DJ; Johnston, PB; Kaufmann, SH; Kurtin, PJ; Link, BK; Loegering, D; Markovic, SN; Maurer, MJ; Micallef, IN; Nowakowski, GS; Peterson, K; Porrata, LF; Schneider, P; Tang, H; Thompson, CA; Weiner, G; Witzig, TE	1

Trials

1 trial(s) available for tipifarnib and Lymphoma

Article	Year
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, Nov-03, Volume: 118, Issue:18 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult	2011

Article

Year

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Blood, 2011, Nov-03, Volume: 118, Issue:18

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult

2011